Table 5.
Change in characteristics of buprenorphine-naloxone group over 6-month follow-up with per-protocol analysis (n=19) and intention-to-treat analysis (n=50)
| Variable | Mean (SD) | One-way repeated-measures ANOVA | Post hoc analysis (Bonferroni test) | ||
|---|---|---|---|---|---|
|
| |||||
| Baseline | 3 months | 6 months | |||
| Per-protocol analysis (n=19) | |||||
| RBI | 3.79 (2.94) | 0.90 (0.81) | 0.90 (0.81) | F# (1-18)=32.64 | T (1-2): P<0.001*** |
| T (2-3): P=NA | |||||
| T (1-3): P<0.001*** | |||||
| Physical QOL | 18.42 (3.13) | 25.79 (3.82) | 26.62 (3.42) | F# (1.259-22.658)=46.512 | T (1-2): P<0.001*** |
| T (2-3): P=0.252 | |||||
| T (1-3): P<0.001*** | |||||
| Psychological QOL | 17.37 (3.58) | 23.16 (1.57) | 23.47 (2.09) | F# (1.233-22.193)=55.221 | T (1-2): P<0.001*** |
| T (2-3): P=0.949 | |||||
| T (1-3): P<0.001*** | |||||
| Social relationship QOL | 7.58 (1.92) | 9.74 (1.52) | 10.00 (1.53) | F# (1.470-26.453)=21.264 | T (1-2): P=0.001*** |
| T (2-3): P=1.000 | |||||
| T (1-3): P<0.001*** | |||||
| Environmental QOL | 21.26 (6.53) | 26.42 (2.27) | 27.05 (1.93) | F# (1.091-19.631)=12.919 | T (1-2): P<0.009*** |
| T (2-3): P=0.311 | |||||
| T (1-3): P=0.001*** | |||||
| SODQ | 42.21 (6.75) | 1.37 (2.75) | 0.00 (0.00) | F# (1.245-22.405)=642.923 | T (1-2): P<0.001*** |
| T (2-3): P=0.132 | |||||
| T (1-3): P<0.001*** | |||||
| COWS | 2.42 (4.36) | 0.11 (0.32) | 0.05 (0.23) | F# (1.002-18.041)=5.607 | T (1-2): P=0.085 |
| T (2-3): P=0.091 | |||||
| T (1-3): P=0.029 | |||||
| ASI total | 0.93 (0.34) | 0.76 (0.83) | 0.59 (0.46) | F# (1.303-23.460)=4.049 | T (1-2): P=0.847 |
| T (2-3): P=0.486 | |||||
| T (1-3): P=0.046* | |||||
| ARC | 21.47 (8.88) | 41.32 (5.59) | 44.16 (4.05) | F# (1.084-19.504)=110.073 | T (1-2): P<0.001*** |
| T (2-3): P<0.001*** | |||||
| T (1-3): P<0.001*** | |||||
| Intention-to-treat analysis (n=50) | |||||
| RBI | 4.00 (3.07) | 2.18 (2.74) | 2.18 (2.74) | F# (1-49)=33.34 | T (1-2): P<0.001*** |
| T (2-3): P=NA | |||||
| T (1-3): P<0.001*** | |||||
| Physical QOL | 18.16 (3.36) | 22.54 (4.82) | 22.86 (4.95) | F# (1.091-53.443)=36.476 | T (1-2): P<0.001*** |
| T (2-3): P=0.253 | |||||
| T (1-3): P<0.001*** | |||||
| Psychological QOL | 16.88 (3.47) | 20.26 (4.02) | 16.88 (3.47) | F# (1.063-52.088)=36.836 | T (1-2): P<0.001*** |
| T (2-3): P=0.925 | |||||
| T (1-3): P<0.001*** | |||||
| Social relationship QOL | 7.30 (2.31) | 8.78 (2.15) | 8.88 (2.20) | F# (1.157-56.689)=21.264 | T (1-2): P<0.001*** |
| T (2-3): P=1.000 | |||||
| T (1-3): P<0.001*** | |||||
| Environmental QOL | 20.86 (6.41) | 23.70 (5.21) | 23.94 (5.30) | F# (1.046-51.249)=12.827 | T (1-2): P<0.001*** |
| T (2-3): P=0.309 | |||||
| T (1-3): P=0.001*** | |||||
| SODQ | 44.62 (6.33) | 17.96 (22.10) | 17.44 (22.44) | F# (1.010-49.474)=74.379 | T (1-2): P<0.001*** |
| T (2-3): P=0.139 | |||||
| T (1-3): P<0.001*** | |||||
| COWS | 2.18 (3.84) | 0.48 (1.62) | 0.46 (1.62) | F# (1.002-49.084)=11.413 | T (1-2): P=0.004** |
| T (2-3): P=0.967 | |||||
| T (1-3): P=0.001*** | |||||
| ASI total | 0.92 (0.39) | 1.04 (1.02) | 0.80 (0.49) | F# (1.247-61.116)=2.921 | T (1-2): P=1.000 |
| T (2-3): P=0.052 | |||||
| T (1-3): P=0.084 | |||||
| ARC | 19.36 (9.27) | 32.08 (12.60) | 33.16 (13.25) | F# (1.031-50.534)=50.032 | T (1-2): P<0.001*** |
| T (2-3): P=0.001*** | |||||
| T (1-3): P<0.001*** | |||||
*Comparison is significant at the level of P=0.05, **Comparison is significant at the level of P=0.01, ***Comparison is significant at the level of P=0.001. #Greenhouse-Geisser value. SODQ - Severity of Opiate Dependence Questionnaire; RBI - Risk Behavior Inventory; COWS - Clinical Opiate Withdrawal Assessment; ARC - Assessment of Recovery Capital; QOL - Quality of life; ASI - Addiction Severity Index; IV - Intravenous; BNX - Buprenorphine-naloxone combination; SD - Standard deviation; ANOVA - Analysis of variance